<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-97463" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sildenafil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Benjamin P.</given-names>
          </name>
          <aff>South University School of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babos</surname>
            <given-names>Mary</given-names>
          </name>
          <aff>LMU-DCOM and Ballad Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mary Babos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-97463.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sildenafil is a medication used in the management and treatment of erectile dysfunction and pulmonary arterial hypertension. It is in the phosphodiesterase-5 inhibitor (PDE5-I) class of medications. This activity describes the indications, actions, adverse effects, and contraindications of sildenafil as an agent in the clinical setting. Knowledge therein is critical for appropriate healthcare team management of patients with erectile dysfunction, pulmonary arterial hypertension, and/or related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of sildenafil in the treatment of erectile dysfunction and pulmonary arterial hypertension.</p></list-item><list-item><p>Describe the clinically important drug interactions of sildenafil.</p></list-item><list-item><p>Outline appropriate monitoring of sildenafil therapy in erectile dysfunction and pulmonary arterial hypertension.</p></list-item><list-item><p>Summarize the role of the interprofessional healthcare team in improving care coordination and communication to improve outcomes related to sildenafil therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=97463&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=97463">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-97463.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <p>Sildenafil was the first phosphodiesterase-5 (PDE5) inhibitor approved for use, receiving US Food and Drug Administration approval for use in erectile dysfunction (ED) on March 27, 1998.<xref ref-type="bibr" rid="article-97463.r1">[1]</xref>&#x000a0;It also has US Food and Drug Administration (FDA) approval for the treatment of World Health Organization (WHO) Group I pulmonary hypertension (also known as pulmonary arterial hypertension [PAH]) in adults to improve exercise tolerance and delay clinical worsening.<xref ref-type="bibr" rid="article-97463.r2">[2]</xref>&#x000a0;Sildenafil-induced delay in clinical worsening is demonstrated when sildenafil was used concomitantly with epoprostenol therapy. Clinical trials have&#x000a0;established effectiveness for short-term use (12-16 weeks) and included patients, mainly patients with New York Heart Association (NYHA) Functional Class II-III symptoms and having idiopathic etiology or connective tissue disease (CTD). However, the addition of sildenafil to bosentan therapy did not result in any improvement in exercise capacity. It is not indicated for children.</p>
        <p>
<bold>Off-labeled Uses</bold>
</p>
        <p>Sildenafil is also occasionally used off-label for the treatment of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Secondary Raynaud phenomenon</p>
          </list-item>
          <list-item>
            <p>Female sexual arousal disorder</p>
          </list-item>
          <list-item>
            <p>Altitude-induced hypoxemia&#x000a0;(as adjunctive therapy)&#x000a0;<xref ref-type="bibr" rid="article-97463.r3">[3]</xref><xref ref-type="bibr" rid="article-97463.r4">[4]</xref><xref ref-type="bibr" rid="article-97463.r5">[5]</xref><xref ref-type="bibr" rid="article-97463.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-97463.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The molecular structure of sildenafil mimics that of cyclic guanosine monophosphate (cGMP). This similarity protects cGMP from degradation because sildenafil can bind to the catalytic site to act as a competitive inhibitor of cGMP-specific PDE5. This enzyme normally catalyzes the breakdown of vasodilatory cGMP. When PDE5 is active, cGMP is degraded, causing the vascular smooth muscle contraction, thereby limiting blood flow.<xref ref-type="bibr" rid="article-97463.r7">[7]</xref> When PDE5 becomes inhibited, the accumulation of&#x000a0;cGMP leads to increased cGMP-dependent protein kinase activity, which phosphorylates multiple targets in the smooth muscle cell. The result of&#x000a0;smooth muscle cell target protein phosphorylation is a decrease in intracellular calcium, increased efflux of potassium, and deactivation of myosin light chain kinase, ultimately causing smooth muscle relaxation.<xref ref-type="bibr" rid="article-97463.r7">[7]</xref><xref ref-type="bibr" rid="article-97463.r8">[8]</xref></p>
        <p>Relaxation of vascular smooth muscle in the corpus cavernosum leads to penile erection when the cavernosal sinusoids engorge with blood to compress the subtunical veins against the tunica albuginea. In patients with vasoactive pulmonary arterial hypertension, vasodilation of the pulmonary artery leads to reduced resistance to blood flow, with subsequent reductions in mean pulmonary arterial pressure.<xref ref-type="bibr" rid="article-97463.r9">[9]</xref></p>
      </sec>
      <sec id="article-97463.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Erectile Dysfunction</bold>
</p>
        <p>Sildenafil is available as oral tablets of 25 mg, 50 mg, and 100 mg strength for ED. Most patients receive a prescription for 50 mg of oral sildenafil, taken as needed approximately 1 hour before sexual activity.<xref ref-type="bibr" rid="article-97463.r7">[7]</xref>&#x000a0;The dose can be titrated upward to a maximum of 100 mg or down to 25 mg based on individual effectiveness and tolerance.</p>
        <p>Patients are advised not to exceed a maximum dosing frequency of once daily. It can be taken 30 minutes to 4 hours before desired intercourse. The onset of action can occur within 30 minutes, while the duration of the effect can last up to 18 hours.</p>
        <p>Consider starting at a dose of 25 mg in patients with hepatic dysfunction (eg, cirrhosis), patients with creatinine clearance (CLcr) less than 30 mL/minute (severe renal impairment), and&#x000a0;patients age 65 years and above, as the administration of sildenafil in these group patients have resulted in higher plasma levels of sildenafil. Patients taking concomitant inhibitors of CYP3A4 may benefit from initiation at the lower dosage.<xref ref-type="bibr" rid="article-97463.r10">[10]</xref></p>
        <p>
<bold>Pulmonary Arterial Hypertension</bold>
</p>
        <p>In the treatment of PAH, sildenafil is available in 20 mg tablets, oral suspension 10 mg/mL, and injectable 10 mg/12.5 mL forms. The recommended dosage for tablet and oral suspension formularies is 5 mg or 20 mg three times daily, 4&#x000a0;to 6 hours apart. Injections are dosed at 2.5 mg or 10 mg three times a day, 4&#x000a0;to 6 hours apart, as an intravenous bolus.<xref ref-type="bibr" rid="article-97463.r11">[11]</xref><xref ref-type="bibr" rid="article-97463.r12">[12]</xref>&#x000a0;Sildenafil injection is only indicated for the continued treatment of PAH when patients are currently on prescribed oral sildenafil treatment and are temporarily unable to take medicine orally.</p>
        <p>No dose adjustment is required in patients with renal impairment (including severe impairment CLcr &#x0003c;30 mL/min). No dose adjustment is required for mild to moderate hepatic impairment. Its use is not studied in patients with severe hepatic impairment.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pediatric Patients:</bold>&#x000a0;Increased mortality with increasing sildenafil dose was observed in a clinical trial of pediatric patients with PAH. Deaths were first reported after approximately&#x000a0;1 year of use, and hence, sildenafil, particularly chronic use, is not recommended in pediatric patients with PAH.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pregnant Women:</bold>&#x000a0;There are increased risks for stroke, heart failure, preterm delivery, and maternal and fetal death for pregnant women with untreated pulmonary arterial hypertension.&#x000a0;There are no adequate and well-controlled studies of sildenafil in pregnant women. Small case studies in pregnant women with PAH indicate a low risk of harm, though caution is warranted.<xref ref-type="bibr" rid="article-97463.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Breastfeeding Women:</bold>&#x000a0;There is a lack of information about the effects of sildenafil on milk production and the effects of sildenafil on breastfed infants.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-97463.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Sildenafil has systemic vasodilatory effects and, as such, should be prescribed with caution to patients who may be sensitive to such blood pressure changes, such as patients with left ventricular outflow obstruction and impaired autonomic control of blood pressure.<xref ref-type="bibr" rid="article-97463.r14">[14]</xref><bold>&#x000a0;</bold>Caution is needed when combining sildenafil with alpha-adrenergic blocking drugs and other antihypertensive agents.<xref ref-type="bibr" rid="article-97463.r15">[15]</xref><xref ref-type="bibr" rid="article-97463.r16">[16]</xref>&#x000a0;</p>
        <p>The use of sildenafil can infrequently result in a prolonged erection lasting more than 4 hours, also known as priapism, which, if left untreated, may result in damage to the penile tissue. Furthermore, sildenafil use requires caution in patients with anatomical deformation of the penis and patients with conditions potentially predisposing them to priapism, such as sickle cell anemia or multiple myeloma.<xref ref-type="bibr" rid="article-97463.r17">[17]</xref>&#x000a0;</p>
        <p>The use of PDE5 inhibitors, such as sildenafil, may increase the&#x000a0;incidence of non-arteritic anterior ischemic optic neuropathy (NAION) in males over age 50. Therefore, patients with a previous history of NAION or with a&#x000a0;"crowded" optic disk&#x000a0;should be prescribed sildenafil with caution.<xref ref-type="bibr" rid="article-97463.r16">[16]</xref>&#x000a0;</p>
        <p>Sildenafil metabolism is catalyzed primarily by CYP3A4 and, to a lesser extent, by CYP2C9; thus, strong inhibitors of these isoenzymes may lead to the accumulation of sildenafil with subsequent toxicity.<xref ref-type="bibr" rid="article-97463.r18">[18]</xref><xref ref-type="bibr" rid="article-97463.r19">[19]</xref> The&#x000a0;coadministration&#x000a0;of sildenafil and ritonavir increased plasma sildenafil concentration (11-fold increase in the&#x000a0;area under the curve due to CYP3A4/2C9 inhibition. Accordingly, caution is necessary for patients already on ritonavir when prescribing sildenafil. The recommendation is&#x000a0;not to exceed a dose of 25 mg of sildenafil&#x000a0;in 48 hours if taking ritonavir.<xref ref-type="bibr" rid="article-97463.r7">[7]</xref><bold>&#x000a0;</bold>Combining sildenafil with the endothelin antagonist bosentan to manage pulmonary arterial hypertension has correlated with increased serum concentrations of bosentan and reduced levels of sildenafil.<xref ref-type="bibr" rid="article-97463.r19">[19]</xref>&#x000a0;Combining sildenafil with other CYP3A4 inducers can similarly lead to reduced sildenafil levels; thus, such combinations are not recommended with chronic sildenafil dosing as performed in managing PAH.<xref ref-type="bibr" rid="article-97463.r20">[20]</xref></p>
        <p>Sildenafil,&#x000a0;at its lowest dose, is recommended when initiating therapy in patients who are on alpha-blockers due to potential systemic hypotension. Caution is also a requirement in patients taking mixed alpha/beta-blockers unless there is specific information regarding coadministration.<xref ref-type="bibr" rid="article-97463.r14">[14]</xref></p>
        <p>
<bold>Adverse Effects&#x000a0;</bold>
</p>
        <p>Doses greater than 100 mg of sildenafil have resulted in no increase in efficacy but an increase in side effects. Patients on sildenafil most commonly (2%) reported headaches, flushing, dyspepsia, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.<xref ref-type="bibr" rid="article-97463.r20">[20]</xref></p>
        <p>Sildenafil has shown associations with&#x000a0;changes in color vision, alterations in light perception, and hazy vision.<xref ref-type="bibr" rid="article-97463.r11">[11]</xref>&#x000a0;Rarely, sildenafil has shown correlations with ototoxicity resulting in hearing loss that may be reversible in some cases.<xref ref-type="bibr" rid="article-97463.r21">[21]</xref></p>
        <p>Epistaxis was reported in 13% of patients taking sildenafil with PAH secondary to connective tissue disorder. Epistaxis was not observed in patients with idiopathic PAH. Epistaxis was reported higher in sildenafil-treated patients with a concomitant oral vitamin K antagonist. The safety of sildenafil is not established in patients with active peptic ulceration or bleeding disorders.</p>
        <p>Cases of a sudden loss of hearing or decrease in hearing, sometimes accompanied by tinnitus and dizziness, with the use of PDE5 inhibitors, including sildenafil. It is not possible to decide if reported cases are related directly to the patient's underlying risk factors attributing to hearing loss, the use of sildenafil, or both or to other factors. Advise patients to seek prompt medical care in case of a sudden loss of hearing or decrease while taking sildenafil.</p>
      </sec>
      <sec id="article-97463.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Nitrates increase cGMP formation, while sildenafil inhibits cGMP degradation, causing the combination to produce severe life-threatening hypotension synergistically; coadministration of sildenafil with nitrates is contraindicated.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www-ncbi-nlm-nih-gov.lmunet.idm.oclc.org/pmc/articles/PMC4943407/#ref7">7</ext-link>] Nitrate administration is safe after five or more sildenafil elimination half-lives (24 hours) have elapsed since the last sildenafil dose administration.<xref ref-type="bibr" rid="article-97463.r15">[15]</xref></p>
        <p>Similarly, severe hypotension from other causes (eg, volume depletion) contraindicates using sildenafil. Other contraindications include hypersensitivity to any component of the formulation, pulmonary veno-occlusion, left ventricular outflow obstruction, PAH associated with sickle cell anemia, and multiple system atrophy.<xref ref-type="bibr" rid="article-97463.r16">[16]</xref>&#x000a0;Ischemic optic neuropathy and inherited degenerative retinal disorders contraindicate sildenafil use; discontinuation of sildenafil is recommended if sudden vision loss occurs.<xref ref-type="bibr" rid="article-97463.r16">[16]</xref></p>
      </sec>
      <sec id="article-97463.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Typically, no regular monitoring is necessary for this medication. Occasionally, patients may be asked to monitor their blood pressure and pulse after being newly prescribed sildenafil, after an increase in dosage, or after adding CYP3A4 inhibitors. During the review of systems, assessment for visual changes is recommended. Patients should also&#x000a0;receive monitoring for signs and symptoms of pulmonary edema when treating pulmonary arterial hypertension.<xref ref-type="bibr" rid="article-97463.r18">[18]</xref></p>
      </sec>
      <sec id="article-97463.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In&#x000a0;healthy subjects, research demonstrated that single doses up to 800 mg had adverse effects similar to those seen in lower doses but with increased frequency and severity. There are no antidotes available for sildenafil. In case of overdose, patients should receive supportive care. Dose-related visual disturbances occurred more frequently at toxic levels, while blood pressure changes showed a low correlation.<xref ref-type="bibr" rid="article-97463.r22">[22]</xref> As sildenafil is highly bound to plasma proteins and not excreted renally, dialysis does not help expedite sildenafil clearance. When considering the duration of toxicity, the activity of N-desmethyl-sildenafil must be regarded as this metabolite retains PDE5 specificity at lower potency, with plasma concentrations approaching 40% of the parent compound.<xref ref-type="bibr" rid="article-97463.r18">[18]</xref></p>
      </sec>
      <sec id="article-97463.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sildenafil is a safe therapeutic option for erectile dysfunction and PAH that has been available on the market for over two decades. Some barriers to successful sildenafil therapy in the treatment of erectile dysfunction include cost and social stigma surrounding erectile dysfunction.<xref ref-type="bibr" rid="article-97463.r23">[23]</xref> All members of the interprofessional health team (clinicians, mid-level practitioners, nurses, and pharmacists) can help eliminate these barriers through compassionate education, a thorough review of systems during clinic visits, and establishing an open line of communication with the patient to better address his medical needs. This will result in better patient outcomes, increased quality of life, and fewer adverse events.&#x000a0;</p>
        <p>The use of sildenafil in the management of erectile dysfunction can significantly impact patient quality of life. ED is associated with depression, anxiety, and loss of self-esteem. A small placebo-controlled 12-week study performed on 512 men with erectile dysfunction used the Self Esteem and Relationship (SEAR) questionnaire to assess the impact of sildenafil treatment on patients. The trial results revealed that sildenafil had improved depression, anxiety, and self-esteem.<xref ref-type="bibr" rid="article-97463.r24">[24]</xref><italic toggle="yes"/></p>
        <p>Current guidelines for treating pulmonary arterial hypertension in adults call for closely coordinated collaboration between the patient's clinical healthcare team and the providers with expertise in the management of PAH. Sildenafil plays a secondary role as an alternative for patients who demonstrate acute vasoreactivity in WHO functional class II to improve their 6-minute walking distance (6MWD) and those in functional class III to improve 6MWD and improve the functional class.<xref ref-type="bibr" rid="article-97463.r25">[25]</xref></p>
      </sec>
      <sec id="article-97463.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=97463&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=97463">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/97463/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=97463">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-97463.s11">
        <title>References</title>
        <ref id="article-97463.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Stecher</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction.</article-title>
            <source>Sex Med Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-128</page-range>
            <pub-id pub-id-type="pmid">30301707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitidieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cirino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>d'Emmanuele di Villa Bianca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sorrentino</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and perspectives in erectile dysfunction in man.</article-title>
            <source>Pharmacol Ther</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>208</volume>
            <fpage>107493</fpage>
            <pub-id pub-id-type="pmid">31991196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roustit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaget</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Khouri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mouhib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lotito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blaise</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seinturier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Subtil</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cracowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Imbert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carpentier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cracowski</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.</article-title>
            <source>Ann Intern Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>20</day>
            <volume>169</volume>
            <issue>10</issue>
            <fpage>694</fpage>
            <page-range>694-703</page-range>
            <pub-id pub-id-type="pmid">30383134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuiten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Rooij</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bloemers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eisenegger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Honk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kessels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kingsberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Derogatis</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>de Leede</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerritsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koppeschaar</surname>
                <given-names>HPF</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Everaerd</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Frijlink</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>H&#x000f6;hle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Lange</surname>
                <given-names>RPJ</given-names>
              </name>
              <name>
                <surname>B&#x000f6;cker</surname>
                <given-names>KBE</given-names>
              </name>
              <name>
                <surname>Pfaus</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.</article-title>
            <source>J Sex Med</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-216</page-range>
            <pub-id pub-id-type="pmid">29289554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeinalzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohagheghzadeh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ahmadinezhad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akbarzadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the effect of Elaeagnus angustifolia flower capsule and sildenafil citrate tablet female sexual interest/arousal disorder in clinical trial study.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>3614</fpage>
            <page-range>3614-3620</page-range>
            <pub-id pub-id-type="pmid">31803662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perimenis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil for the treatment of altitude-induced hypoxaemia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2005</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>835</fpage>
            <page-range>835-7</page-range>
            <pub-id pub-id-type="pmid">15934909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCullough</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Four-year review of sildenafil citrate.</article-title>
            <source>Rev Urol</source>
            <year>2002</year>
            <volume>4 Suppl 3</volume>
            <issue>Suppl 3</issue>
            <fpage>S26</fpage>
            <page-range>S26-38</page-range>
            <pub-id pub-id-type="pmid">16986012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Mwamukonda</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>The future is today: emerging drugs for the treatment of erectile dysfunction.</article-title>
            <source>Expert Opin Emerg Drugs</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>467</fpage>
            <page-range>467-80</page-range>
            <pub-id pub-id-type="pmid">20415601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallah</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recent strategies in treatment of pulmonary arterial hypertension, a review.</article-title>
            <source>Glob J Health Sci</source>
            <year>2015</year>
            <month>Jan</month>
            <day>26</day>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-22</page-range>
            <pub-id pub-id-type="pmid">25946920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muirhead</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Wulff</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Fielding</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kleinermans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buss</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-107</page-range>
            <pub-id pub-id-type="pmid">10930961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coons</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolodziej</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2019</year>
            <month>Nov</month>
            <day>22</day>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">31758342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Yow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Toews</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Anstrom</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <collab>IPFnet Investigators</collab>
            </person-group>
            <article-title>Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.</article-title>
            <source>Chest</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>143</volume>
            <issue>6</issue>
            <fpage>1699</fpage>
            <page-range>1699-1708</page-range>
            <pub-id pub-id-type="pmid">23732584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeSantis</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Treatment of pulmonary arterial hypertension in pregnancy.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>64</volume>
            <issue>18</issue>
            <fpage>1922</fpage>
            <page-range>1922-6</page-range>
            <pub-id pub-id-type="pmid">17823103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cheitlin</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.</article-title>
            <source>Urology</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>3 Suppl</issue>
            <fpage>47</fpage>
            <page-range>47-60</page-range>
            <pub-id pub-id-type="pmid">17011375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Dec</month>
            <day>26</day>
            <volume>96</volume>
            <issue>12B</issue>
            <fpage>42M</fpage>
            <page-range>42M-46M</page-range>
            <pub-id pub-id-type="pmid">16387566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Osterloh</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>689</fpage>
            <page-range>689-702</page-range>
            <pub-id pub-id-type="pmid">16883306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ekeke</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Omunakwe</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Eke</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of priapism in adult men.</article-title>
            <source>Int Surg</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>552</fpage>
            <page-range>552-7</page-range>
            <pub-id pub-id-type="pmid">25785343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramani</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2010</year>
            <month>May</month>
            <day>25</day>
            <volume>4</volume>
            <fpage>61</fpage>
            <page-range>61-70</page-range>
            <pub-id pub-id-type="pmid">20531962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorhies</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Drug treatment of pulmonary hypertension in children.</article-title>
            <source>Paediatr Drugs</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-65</page-range>
            <pub-id pub-id-type="pmid">24114695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhariwal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bavdekar</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil in pediatric pulmonary arterial hypertension.</article-title>
            <source>J Postgrad Med</source>
            <year>2015</year>
            <season>Jul-Sep</season>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-92</page-range>
            <pub-id pub-id-type="pmid">26119438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skeith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Farquhar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.</article-title>
            <source>J Popul Ther Clin Pharmacol</source>
            <year>2013</year>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>e128</fpage>
            <page-range>e128-31</page-range>
            <pub-id pub-id-type="pmid">23756362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giuliano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martin-Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raillard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.</article-title>
            <source>Int J Clin Pract</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-55</page-range>
            <pub-id pub-id-type="pmid">19900167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezaee</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Munarriz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>A Review of Economic Evaluations of Erectile Dysfunction Therapies.</article-title>
            <source>Sex Med Rev</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>497</fpage>
            <page-range>497-503</page-range>
            <pub-id pub-id-type="pmid">31326359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Althof</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>O'leary</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cappelleri</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hvidsten</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stecher</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <collab>International SEAR Study Group</collab>
            </person-group>
            <article-title>Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial.</article-title>
            <source>J Sex Med</source>
            <year>2006</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>521</fpage>
            <page-range>521-9</page-range>
            <pub-id pub-id-type="pmid">16681478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-97463.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klinger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bossone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duvall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fagan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frantsve-Hawley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Sederstrom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-586</page-range>
            <pub-id pub-id-type="pmid">30660783</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
